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ABSTRACT
Background: Female age-related estrogen deficiency increases the
risk of osteoporosis, which can be effectively treated with the use of
hormone replacement therapy. However, hormone replacement ther-
apy is demonstrated to increase cancer risk. Bioavailable isofla-
vones with selective estrogen receptor affinity show potential to
prevent and treat osteoporosis while minimizing or eliminating car-
cinogenic side effects.
Objective: In this study, we sought to determine the beneficial
effects of a bioavailable isoflavone and probiotic treatment against
postmenopausal osteopenia.
Design: We used a novel red clover extract (RCE) rich in isoflavone
aglycones and probiotics to concomitantly promote uptake and a
favorable intestinal bacterial profile to enhance isoflavone bioavail-
ability. This was a 12-mo, double-blind, parallel design, placebo-controlled,
randomized controlled trial of 78 postmenopausal osteopenic women
supplemented with calcium (1200 mg/d), magnesium (550 mg/d), and
calcitriol (25 mg/d) given either RCE (60 mg isoflavone aglycones/d and
probiotics) or a masked placebo [control (CON)].
Results: RCE significantly attenuated bone mineral density (BMD)
loss at the L2–L4 lumbar spine vertebra (P , 0.05), femoral neck
(P , 0.01), and trochanter (P , 0.01) compared with CON
(20.99% and 22.2%; 21.04% and 23.05%; and 20.67% and
22.79, respectively). Plasma concentrations of collagen type 1
cross-linked C-telopeptide was significantly decreased in the RCE
group (P , 0.05) compared with CON (29.40% and 26.76%, re-
spectively). RCE significantly elevated the plasma isoflavone con-
centration (P , 0.05), the urinary 2-hydroxyestrone (2-OH) to
16a-hydroxyestrone (16a-OH) ratio (P , 0.05), and equol-producer
status (P , 0.05) compared with CON. RCE had no significant
effect on other bone turnover biomarkers. Self-reported diet and
physical activity were consistent and differences were nonsignifi-
cant between groups throughout the study. RCE was well tolerated
with no adverse events.
Conclusions: Twice daily RCE intake over 1 y potently attenuated
BMD loss caused by estrogen deficiency, improved bone turnover,
promoted a favorable estrogen metabolite profile (2-OH:16a-OH),
and stimulated equol production in postmenopausal women with
osteopenia. RCE intake combined with supplementation (calcium,
magnesium, and calcitriol) was more effective than supplementation
alone. This trial was registered at clinicaltrials.gov as NCT02174666.
Am J Clin Nutr 2017;106:909–20.
Keywords: isoflavone, bone turnover, bioavailability, probiotics,
osteopenia, postmenopause, equol, bone density
INTRODUCTION
The natural decline in endogenous estrogen during meno-
pause reduces bone mineral density (BMD) and incurs negative
changes to bone microarchitecture, and this increases the risk of
osteoporosis and fracture in women (1, 2). Menopausal women
lose on average 225% BMD/y, and after the final menstrual
period they lose 123% BMD/y (3, 4). Calcium and vitamin D
(CaD) are the first-choice prophylactic treatment of clinicians
in the management of postmenopausal osteopenia. The National
Osteoporosis Foundation (NOF) recommends intakes of 1200 mg
Ca/d and 20–25 mg vitamin D/d in these patients. Meta-analyses
have shown that CaD alone can reduce total- and hip-fracture risk
by 15% and 30%, respectively, in older patients ($65 y of age)
Supported by Future Food Innovation, Danish Agency for Science,
Technology and Innovation grant 1355-00153A, and Aase and Ejnar Dan-
ielsens Fund grant 10-001451.
Supplemental Tables 1 and 2 are available from the “Online Supporting
Material” link in the online posting of the article and from the same link in
the online table of contents at http://ajcn.nutrition.org.
Address correspondence to PBJ (e-mail: per.bendix.jeppesen@clin.au.dk).
Abbreviations used: BMC, bone mineral content; BMD, bone mineral
density; BP, blood pressure; CaD, calcium and cholecalciferol; CDM, cal-
cium, vitamin D, and magnesium; CON, control; CTx, collagen type 1 cross-
linked C-telopeptide; DXA, dual-energy X-ray absorptiometry; ER, estrogen
receptor; ET, estrogen therapy; FN, femoral neck; L2–L4, lumbar spine
vertebra L2–L4; NOF, National Osteoporosis Foundation; PAL, physical
activity level; RANKL, receptor activator of nuclear factor k-B ligand; RC,
red clover; RCE, red clover extract; RCT, randomized controlled trial; TC,
total cholesterol; UHPLC-MS/MS, ultra HPLC-tandem mass spectrometry;
2-OH, 2-hydroxyestrone; 16a-OH, 16a-hydroxyestrone.
Received January 19, 2017. Accepted for publication June 28, 2017.
First published online August 2, 2017; doi: https://doi.org/10.3945/ajcn.
117.153353.
Am J Clin Nutr 2017;106:909–20. Printed in USA.  2017 American Society for Nutrition 909
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/106/3/909/4822361 by guest on 24 Septem
ber 2018
(5, 6). Randomized controlled trials (RCTs), observational
studies, and meta-analyses suggest that a ratio of calcium to
magnesium of 2.8:1 is most optimal for bone heath (7). Large
RCTs support the hypothesis that estrogen therapy (ET) is also
effective in the prevention and treatment of estrogen-deficient
osteoporosis in postmenopausal women (8, 9). ET use remains
controversial because it has been associated with cancer risk in
estrogen receptor (ER)-a rich tissues (i.e., breast, ovaries, and
endometria) (10). Meta-analyses indicate that the RR of ovar-
ian cancer with ET use ranges from 1.19 to 1.46 and that ET
use for ,5 y has a RR of 1.43 (11–14). ET cessation leads
to rapid loss of the osteoprotective effects against fracture
(15, 16). Considering the treatment duration for maintenance
of bone health during postmenopause and the associated risks
of prolonged ET use, it is of clinical value to develop effective
treatments with minimal side effects that are suitable for
longer-term use. Isoflavones naturally occur in legumes, such
as soy and red clover (RC) (17). Whereas estrogen acts as an
agonist with binding affinity for ERa (highly expressed in
cancer-sensitive tissues) and ERb, isoflavones retain selective
affinity for ERb, which presents in tissues requiring certain
stimulation by estrogen to function normally (e.g., bone tissue,
bone marrow, adipose, brain, kidney, endothelial cells, and
liver) (18, 19). Thus, isoflavones can adopt the regulatory roles
of estrogen without incurring equivalent side effects in sensi-
tive tissues (20). Isoflavones have a favorable safety profile in
humans and are staple components in Indo-Asian diets (21).
Analysis of dietary isoflavone intake and breast cancer risk in a
multiethnic cohort of 84,450 women showed no significant
association, and a 13-y follow-up indicated a protective effect in
the highest intake quartile (20.32178.7 mg isoflavone/d) (22).
Isoflavones may also regulate hepatic cytochrome P450 enzymes
and promote favorable estrogen metabolism by upregulating the
ratio of 2-hydroxyestrone (2-OH) to 16a-hydroxyestrone (16a-OH)
metabolites (23, 24). 16a-OH is potentially more genotoxic
and estrogenic than its 2-OH counterpart, which has minimal
estrogenic potential and may retain cancer protective effects
(25). Various isoflavones have distinct bioactivity and RC
offers a unique profile of isoflavones (formononetin and bio-
chanin A) (26). Enzymatic methods and probiotics can be used
to increase isoflavone uptake, and fermented isoflavone pre-
parations (aglycone rich) have demonstrated higher bioavail-
ability than unfermented (glycoside rich) (27–29). In vivo trials
in female rats with induced bone loss (ovariectomized) support
the theory that formononetin in particular may have anti-
resorptive and anabolic properties (30–36). Human RCTs
have also shown promising effects of isoflavones for reducing
bone resorption markers (37–39). We have previously ex-
ecuted a 3-mo RCT with healthy menopausal women receiv-
ing an aglycone-rich RC isoflavone (37 mg/d) and combined
probiotic RC extract (RCE). The results indicated that RCE
attenuated BMD loss at the lumbar spine vertebra L22L4
(L22L4) region (40). The present clinical trial aims to de-
termine whether long-term RCE is more effective than tra-
ditional CaD treatment of postmenopausal osteopenia. The
primary endpoint was the effect of RCE against BMD loss. Sec-
ondarily, we determined the effects of RCE on bone turnover
markers, estrogen metabolites, plasma isoflavone concentra-
tion, equol-producer status, plasma lipid concentrations, and
blood pressure (BP).
METHODS
Participants and study design
This study was a 12-mo, parallel-design, placebo-controlled,
double-blind RCT. A total of 121 postmenopausal women
with established osteopenia were screened and recruited from a
community in northern Denmark (Hospital Vendsyssel, Hjoer-
ring, Denmark). The clinical aspects of the study were carried out
from November 2013 to February 2015, including screening,
recruitment, and the trial period. Participants were recruited
through advertisements (local newspaper, flyers, posters, and
local radio) or referred to the project by general practitioners in
the local area. Potential candidates were required to contact the
project team over the phone for prescreening, at which point
contact information and pre-eligibility information were col-
lected. To be considered, participants had to be female, $1 y
postmenopause, and have an established T score of 21 to 22.5
and an age of 60285 y. Approved participants were sent doc-
uments containing participant information about the study, par-
ticipants’ rights in a biomedical research project (prepared by
the Danish Scientific Research Ethics Committee), and a writ-
ten consent form; they were then given $2 wk to read the infor-
mation. Thereafter, participants were invited to an oral assessment
and screening day (week 22); participants were required to
provide a previous dual-energy X-ray absorptiometry (DXA)
scan indicating osteopenia and their habitual medicine. Candi-
dates were informed that participation was voluntary and were
given a comprehensive briefing of the study. After the oral brief-
ing, eligibility assessment, and obtainment of participant consent,
basal parameters were collected, including anthropometric mea-
surements (waist circumference, BP, and BMI), and a DXA scan.
All participants consented to keep habitual diet and exercise
constant for the duration of the study.
Eighty-five participants were found to be eligible and were
included in the study, and these participants were randomized
into either the control (CON) extract group or the RCE treatment
group by a computer-generated code (simple randomization). At
the hospital during the baseline visit (at week 0), participants
collected their supplements and extract, undertook 24-h ambu-
latory BP, submitted fasted blood and urine samples for analysis,
completed physical activity level (PAL) questionnaires, and were
given 3-d diet diaries with instructions and a return envelope
addressed to the hospital. Inclusion criteria were as follows:
postmenopausal women aged 60–85 y, osteopenia (T score: 21
to 22.5), and a BMI (in kg/m2) of 20240. Exclusion criteria
were as follows: medicinal treatment of osteoporosis within
the last 3 mo (bisphosphonates, parathyroid hormone, stron-
tium ranelate, or denosumab), treatment with estrogen or hor-
mone therapy in the last 3 mo, treatment with estrogen agonist
or antagonist products (raloxifene or tamoxifen), T score #23
or $21, a diet rich in or supplementation with isoflavones,
vitamin K supplementation, participation in other clinical trials
within the past 3 mo, severe cardiovascular, psychiatric, neu-
rological, or kidney disease, a history of cancer, a history of
alcohol or substance abuse, high BP (.160/110 mm Hg), met-
abolic disorders, and pregnancy or breastfeeding. A total of 78
participants successfully completed the study (see Figure 1 for
consort flow diagram). The trial was executed in accordance
with guidelines laid down by the Declaration of Helsinki and
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was approved by the Danish Research Ethics Committee (no. 1–
16-02-466-13) and the Danish Data Protection Agency. In line
with the International Committee of Medical Journal Editors, the
study protocol was registered at clinicaltrials.gov (NCT02174666).
This intervention study was a double-blind, head-to-head RCT
with participants treated either with twice daily RCE (2 3
95 mL = 60 mg isoflavones/d total) plus vitamin and mineral
tablets containing 1040 mg Ca, 487 mg Mg, and 25 mg vitamin
D (CDM)/d or masked placebo extract plus CDM/d for 12 mo
(Figure 2).
RCE and CON extracts
The RCE was produced by Herrens Mark ApS. RC plants for
the production of RCE were grown by Herrens Mark ApS. A
heterogeneous culture (proprietary) of probiotic lactic acid
bacteria was added to pressed RCE to facilitate cold fermentation
and improve bioavailability. Standardization of postfermentation
aglycone content was determined by HPLC coupled with diode-
array detection and mass spectrometry (DB Laboratory A/S). To
mask taste and appearance of the RCE, stevia and a natural sugar-
free raspberry or orange flavoring was added. For each batch,
90 L of either water (placebo) or RCE were sweetened with 18 g
stevia and 6.3 L of sugar-free raspberry or orange flavoring. The
placebo extract comprises 90 L of water mixed with 250 g brown
food coloring (ammoniated caramel) (Kavli) to achieve likeness
in appearance to the RCE. Portions of extract (95 mL each) were
sealed in identical aluminum sachets, and these were consumed
twice daily with a meal. The RC and placebo sachets were packed
FIGURE 1 Consort participant flowchart of participation through the present study.
FIGURE 2 A schematic representation of the study design. The far left shows 2 groups: those receiving RCE and those receiving the control (placebo).
Screening and briefing are scheduled at 2 wk prior (22) to project and include assessment of basal parameters. Postscreening and postrandomization
administration of either placebo or RCE took place at 0 (baseline). DXA scans took place at 0 and 12 mo. At months 0, 6, and 12, fasted blood and urine
samples were taken and analyzed, along with BP. Extract and supplement collection took place at 0, 3, 6, and 9 mo; return of empty pill containers and
extract sachets took place at 3, 6, 9, and 12 mo for compliance. BP, blood pressure; DXA, dual-energy X-ray absorptiometry; RCE, red clover extract;
w, weeks.
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in identical, sealed, white cardboard boxes and coded with 1 or
2 denoting groups. All participants returned empty containers,
which were collected by the research team and recorded to
monitor compliance (set to 95%). All participants and the re-
search team were blinded and had no knowledge of the content of
the boxes throughout the course of the study, the actual contents
of the boxes with 1 and 2 codes were revealed at completion of
the study by an independent third party from Herrens Mark ApS.
Boxes were handed out at baseline and at 3, 6, and 9 mo.
Isoflavone quantitation by liquid chromatography-mass
spectrometry and CaD supplements
Isoflavone composition and quantitation analysis of the RCE
was performed by DB Laboratory A/S. Quantitation was assessed
by HPLC coupled with diode-array detection and mass spec-
trometry on a Summit LC/MS system consisting of a quaternary
pump (P680 LPG), autosampler (ASI 100T), column oven (TCC-
100) UV detector (PDA-100), and MS detector (Surveyor MSD
Plus), all from Dionex. Four standards of the primary isoflavones
(genistein, daidzein, formononetin, and biochanin A) and 1 gly-
coside derivative (Ononin) were obtained from Sigma Aldrich
DenmarkA/S and used for the determination of isoflavones in RCE.
The RCE was diluted 10 times (from 50 to 5 mL) by methanol
before analysis (for content, see Supplemental Table 1). Calcium
and multivitamin supplements comprising the CDM were obtained
from Fitness Pharma (for contents, see Supplemental Table 2).
Participants were required to take 1 calcium supplement, 1 multi-
vitamin, and either 95 mL of extract (RCE group) or placebo with
no isoflavones (CON group) in the morning and evening with
a meal; in all, this amounted to a total daily intake of 57.45 mg
isoflavones (55.84 mg aglycones/d) for the RCE group and
0 mg isoflavones/d for the CON group.
Blood and urine samples
Fasting blood and urine samples were collect from participants
between 0800 and 0900 at baseline and at 6 and 12 mo. On
collection, all EDTA plasma and urine samples were frozen and
kept at –808C (Department of Clinical Biochemistry, Hospital
Vendsyssel) until analysis.
Plasma lipids
Blood plasma lipid concentrations were determined with the
use of absorbance photometry by using the Roche Cobas C111
Clinical Chemistry Analyzer (Roche Diagnostics, GmbH). Total
cholesterol (TC), HDL, and triglyceride concentrations were
determined with the use of direct and enzymatic assay (Roche
Diagnostics, GmbH). Final LDL concentrations were calculated
with the use of the Friedewald equation [i.e., LDL = TC2HDL2
VLDL (estimated as triglycerides/50)].
Dual-energy X ray absorptiometry
DXA was performed by the same health care professionals
with the use of an XR 800 DXa scanner (Illuminatus software,
version 4.2.4; Norland, CooperSurgical) at the L22L4 region,
femoral neck (FN), and trochanter sites at baseline and 12 mo.
DXAwas used to determine bone mineral content (BMC), BMD,
and T score at each site.
Biomarkers of bone turnover
Measurements of biomarkers of bone turnover were performed
on freshly thawed aliquots by a single analyst blinded to clinical
status. Plasma concentrations of collagen type 1 cross-linked
C-telopeptide (CTx), osteocalcin, and procollagen type I N-
terminal propeptide were measured on an automated analyzer
according to the manufacturer’s instructions. Plasma concentra-
tions of free non–osteoprotegerin-bound receptor activator of
nuclear factor k-B ligand (RANKL) and plasma concentra-
tions of undercarboxylated osteocalcin were measured by ELISA
according to the kit manufacturer’s instructions. The manufacturer-
supplied analytic variation coefficients were as follows: CTx,
procollagen type I N-terminal propeptide, and osteocalcin (Roche
Diagnostics):,6%,,4%, and,2%, respectively; undercarboxylated
osteocalcin (Takara Bio) ,10%, and RANKL (Biomedica) ,3%.
Analyses were carried out by the same technicians at Aalborg
University Hospital. The signaling marker osteoprotegerin (R&D
Systems) had a manufacturer-coefficient of 6% and was performed
by a single technician at Odense University Hospital.
Urinary estrogen metabolites
Concentrations of the estrogen metabolites 16a-OH and 2-OH
were determined in triplicate for urine samples by enzyme im-
munoassay (Estramet 2/16 ELISA; IBL International). Before
analysis, glucuronides and sulfates were hydrolyzed enzymati-
cally, and the procedure was performed according to the man-
ufacturers’ instructions (41). The obtained interbatch precision
for 2-OH and 16a-OH was 10.9% and 9.1%, respectively. Analyses
were carried out by the same technicians at Aalborg University
Hospital.
Plasma isoflavone concentration
The concentrations of the isoflavones in the plasma samples
were determined by ultra-HPLC–tandem mass spectrometry
(UHPLC-MS/MS) (Agilent) at Odense University Hospital. Plasma
EDTA samples (250 mL) were mixed in tubes with 250 mL buffer
(1 mL acetic acid glacial, 4.103 g sodium acetate trihydrate, and
500 mL water) at pH 4.9 containing 0.00625 g (250 U) sulphatase
(Sigma Aldrich). Thereafter, 25 mL (2500 U) b-glucuronidase
(Sigma Aldrich) was added and vortexed. Samples were incu-
bated for 4 h at 378C in an incubator. After removal from the
incubator, 250 mL of HPLC-grade acetonitrile (Sigma Aldrich)
was added to precipitate proteins. Samples were then centrifuged
at 10,000 3 g for 10 min, and the supernatant extracted was
transferred by syringe and filtered (0.22-mm pore filter) into
HPLC vials. Purified ($99.9%) formononetin, biochanin A,
daidzein, genistein, and equol standards (Sigma Aldrich) were
acquired for generating calibration curves. Plasma isoflavone
concentration was determined as the sum of formononetin,
biochanin A, daidzein, genistein and equol concentrations detected
in plasma by UHPLC-MS/MS.
UHPLC-MS/MS was performed on a 1290 Infinity UHPLC
composed of a pump (G4220A), an autosampler (G4226A), a
thermostat (G1330B), and a column oven (G1316C) and hy-
phenated with a 6460 triple-quadrupole mass spectrometer
(Agilent). The system was controlled by MassHunter Worksta-
tion software (version B.08.00, build 8.0.8023.0). Separation of
the analytes was achieved on an Agilent Eclipse Plus C18 Rapid
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Resolution High Definition column (1.8 mm, 2.53 50 mm). The
column oven temperature was adjusted to 608C. Solvent A was
0.1% (volume:volume) formic acid in water, and solvent B was
0.1% (volume:volume) formic acid in acetonitrile. The flow rate
was set to 0.4 mL/min. The injected sample volume was 0.5 mL.
The gradient elution profile was as follows: linear gradient from
1% B at 0 min to 95% B at 15 min, then a return to 1% B from
15 to 16 min, followed by an isocratic post-run equilibration at
1% B. The Agilent Jet Stream electrospray ionisation source of
the mass spectrometer was operated in the positive mode. The
source parameters were as follows: gas temperature: 3508C, gas
flow: 10 L/min, nebulizer: 241.32 kPa, sheath gas temperature:
4008C, sheath gas flow: 12 L/min, and the capillary: 4500 V and
32 nA. The experiments were conducted in dynamic multiple
reaction monitoring. Nitrogen was used as collision gas. Au-
thentic standards of the isoflavones formononetin, biochanin A,
daidzein, genistein, and equol were used for identification and
quantification.
Equol-producer status
The time-resolved fluoroimmunoassay (Labmaster, Ltd.) for
equol determination in plasmawas used at baseline and 6mo. The
kit required the use of 200 mL of plasma. Plasma samples were
treated with enzymatic hydrolysis in acetate buffer (0.1 M,
pH 5 + 0.2 U/mL glucuronidase + 0.2 U/mL sulphatase) in-
cubated at 378C overnight. Thereafter, equol was extracted in
1.5 mL diethyl ether, transferring equol from the polar plasma or
water phase to the apolar ether phase. The sample was frozen
and ether extracted, water was then thawed and re-extracted with
ether, and this was then combined with the previously extracted
ether and finally evaporated. A total of 200 mL of assay buffer
containing lyophilized europium-labeled equol was added to the
tubes, and 20 mL of the sample was taken for time-resolved
fluoroimmunoassay. Europium-labeled equol and sample equol
competed for goat anti-rabbit IgG on low-fluorescence micro-
titer plates that bind anti-equol antibody–forming fluorescent
chelates. Samples were analyzed by an EnVision multimode
plate reader (PerkinElmer), subsequent data were assessed with
the use of WorkOut 2.5 (PerkinElmer). Equol-producer status in
this study was defined as a plasma concentration of $15 nmol/L
in accordance with Nettleton et al. (42).
Ambulatory BP
Twenty-four–hour BP measurements were taken at baseline
and at 12 mo with the use of the SpaceLab monitor (SpaceLabs
Medical) and data was assessed by SpaceLabs software. Mean
arterial pressure, heart rate, and systolic and diastolic BP were
taken at specified time intervals. Participants were required to
abstain from medium and heavy exercise for the duration of
24-h testing and to note down when they woke up and went to
sleep.
Three-day dietary intake
Habitual diets were collected with the use of a 3-d diet diary
(3 consecutive days, including 1 weekend day) at baseline and at
6 and 12 mo. Participants were instructed verbally and given a
guide (including examples) by the research team specifying how
to fill in the diary over the 3 d. Before consumption, all food items
were weighed individually with the use of household scales. To
minimize under-reporting or oversight, participants were in-
structed to record continuously. Completed diaries were handed
in to the research team and analyzed with the use ofMADLOGVita
(MADLOG ApS; https://www.madlogvita.dk/da/), an online diet
and nutrition calculation program. MADLOGVita was used to
estimate the following: intake; energy; macronutrients (protein,
carbohydrates and fat); and micronutrients (vitamin D, vitamin K,
calcium, and magnesium). This program collects nutritional data
from FoodComp and Danish food manufacturers; it is Denmark’s
most complete database with .14,500 specific Danish food
products.
PAL questionnaire
PAL questionnaires were completed at baseline and at 6 and
12 mo. It comprises 4 central multiple choice questions regarding
current training and daily physical activity. Scores for each range
from 1 to 4, where higher scores indicate lower PAL.
Compliance and adverse events
Participants were required to collect and return empty extract
sachets and supplement containers at 3, 6, 9, and 12 mo. These
sachets and containers were counted by the research team, and
compliance was calculated from the number returned. At least
90% of empty sachets and containers were required for partic-
ipants to fulfill the compliance criteria. At the end of the study,
participants achieved a mean (6) compliance rate of 96.4% 6
3.64%. Adverse events were reported by participants via the
project telephone number or during hospital visits. The RCE
was well tolerated and there were no significant adverse events.
Statistics
Statistical analysis included all participants who completed the
study. Data were analyzed with the use of StataIC statistical
software (version 11.2). Graphs were created by GraphPad Prism.
version 4 (GraphPad Software, Inc.). All data were tested for
normal distribution by way of visual inspection (quantile-quantile
plots, histograms, and box plots) and by the D’Agostino-Pearson
test. Between group differences in baseline and intergroup
change over the duration of the study were determined for each
parameter with the use of unpaired Student’s t tests. Paired
Student’s t tests were used to assess intragroup differences from
baseline to 12 mo. For parameters with .2 groups, 2-way and
repeated-measures (within-subject) ANOVA were used. When
significant main effects were detected (P , 0.05), the Bonfer-
roni multiple comparisons test was applied to compare data. All
absolute and ratio data are presented in text and tables as
means6 SEMs, change data from baseline to 12 mo are presented
as means (95% CIs). In all cases, a P value ,0.05 was considered
significant.
Power calculation
To determine the required number of participants, the following
equation was used:
N = (Z a + Z b) 2 3 s2/MIREDIF2 (1)
The minimum relevant difference was set at 1.7; a was 5%,
b was 20%, and the spread (s) was set to 2.5. The minimum
BIOAVAILABLE ISOFLAVONES FOR MENOPAUSE SYMPTOMS 913
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number of participants required to complete the study was 68
(34 in each group). Due to the long duration of the study, 25%
was added to the final N value to account for dropouts and
losses, and the final total number of participants to include was
85. Effect size was based on BMD data of postmenopausal women
after 1 y of soy treatment from Lydeking-Olsen et al. (43).
RESULTS
Baseline characteristics
Except for significantly higher (P , 0.034) BMC at the tro-
chanter in the CON group (8.46 6 0.27 g) compared with the
RCE group (7.67 6 0.28 g), there were no significant intergroup
differences in any of the baseline parameters listed in Table 1. A
total of 78 participants successfully completed the trial and were
included in all analyses (CON group: n = 40; RCE group: n = 38).
DXA
The change in BMD (P = 0.043) and T score (P = 0.045)
showed a significantly greater decrease in the lumbar spine of
the CON group [BMD: 20.022 g/cm2 (20.032, 20.012 g/cm2);
T score: 20.2 (20.29, 20.11)] than the RCE group [BMD:
20.0085 g/cm2 (20.017, 0.00006 g/cm2); T score: 20.08
(20.16, 0.0001)] after 12 mo of treatment (Figure 3). Similar
results were found at the FN, where BMD (P = 0.0059) and T
score (P = 0.0061) showed a significantly greater decrease than
the CON group [BMD: 20.022 g/cm2 (20.03, 20.015 g/cm2);
T score: 20.19 (20.25, 20.12)] than the RCE group [BMD:
20.008 g/cm2 (20.015, 0.00003 g/cm2); T score: 20.06
(20.13, 20.0001)]. A significantly greater reduction from baseline
to 12 mo was also seen in the trochanter for BMD (P = 0.03) and
BMC (P = 0.034) in the CON group [BMD: 20.017 g/cm2
(20.025, 20.008 g/cm2); BMC: 20.54 g (20.79, 20.3 g)]
compared with the RCE group [BMD: 20.004 g/cm2 (20.01,
0.004 g/cm2); BMC: 20.23 g (20.39, 20.07 g)]. There were no
significant intergroup differences in the change in BMC at the
lumbar spine or the FN.
Bone biomarkers
A significant reduction (P = 0.045) in bone resorption marker
plasma CTx concentration was found in the RCE group
[20.04 ng/mL (20.09, 0.01 ng/mL)] compared with the CON
group [0.03 ng/mL (20.02, 0.07 ng/mL)]. There were no sig-
nificant differences between groups in any of the other bone
biomarkers (Table 2). Both groups saw a significant increase in
osteoprotegerin concentration (P , 0.001) from baseline: the
RCE group increased by 480.1 ng/mL (2138, 1273 ng/mL), and
the CON group by 420.8 ng/mL (2278, 1094 ng/mL).
Plasma isoflavone concentration
The isoflavone concentration was significantly elevated
(P = 0.0094) in the RCE group [3933 ng/mL (627.6, 7238 ng/mL)]
from baseline to 12 mo of treatment (Figure 4) compared with
the CON group [2322.7 ng/mL (2608.1, 237.23 ng/mL)].
Equol-producer status
At baseline, the mean equol concentrations for the CON and
RCE groups were 2.94 6 0.64 nmol/L and 3.37 6 0.42 nmol/L,
respectively. None of the participants were found to be equol
producers at baseline, and at 6 mo, there was a significant in-
crease (P , 0.0001) in equol concentration for the RCE group
TABLE 1
Baseline characteristics of 78 participants that completed the study1
CON (n = 40) RCE (n = 38) P2
Age, y 62.85 6 0.99 60.84 6 1.07 0.17
Height, m 1.63 6 0.01 1.64 6 0.01 0.87
Weight, kg 71 6 2.15 66.61 6 1.81 0.12
BMI, kg/m2 26.65 6 0.81 24.84 6 0.62 0.08
Waist,3 m 0.92 6 0.02 0.86 6 0.02 0.06
Ambulatory blood pressure (24 h)
Systolic,3 mm Hg 125.7 6 1.88 121.8 6 1.66 0.13
Diastolic, mm Hg 76.47 6 1.29 76.16 6 1.10 0.52
DXA
L2–L4 BMD, g/cm2 0.86 6 0.10 0.87 6 0.13 0.82
L2–L4 BMC, g 39.47 6 1.05 39.77 6 1.06 0.98
L2–L4 T score 21.97 6 0.16 21.96 6 0.18 0.82
FN BMD, g/cm2 0.74 6 0.01 0.72 6 0.01 0.46
FN BMC, g 3.58 6 0.07 3.55 6 0.07 0.74
FN T score 21.55 6 0.09 21.64 6 0.09 0.47
Troch BMD 0.60 6 0.01 0.58 6 0.01 0.26
Troch BMC 8.46 6 0.27 7.67 6 0.28 ,0.05
Lipids
Total cholesterol, mmol/mL 5.64 6 0.16 5.54 6 0.14 0.63
LDL, mmol/mL 3.37 6 0.14 3.28 6 0.14 0.65
HDL, mmol/mL 1.82 6 0.08 1.81 6 0.07 0.92
Triglycerides,3 mmol/mL 1.38 6 0.10 1.16 6 0.06 0.12
Phytoestrogen
Plasma isoflavones, ng/mL 629.0 6 120.2 714.0 6 133.3 0.64
Urinary estrogen metabolites
2-OH,3 ng/mL 10.44 6 1.17 12.11 6 2.15 0.84
16a-OH,3 ng/mL 4.45 6 0.95 4.91 6 1.00 0.54
2-OH:16a-OH ratio,2 ng/mL 3.13 6 0.27 2.77 6 0.19 0.60
1Data are presented as means 6 SEMs. BMC, bone mineral content;
BMD, bone mineral density; CON, control; DXA, dual-energy X-ray ab-
sorptiometry; FN, femoral neck; L2–L4, lumbar spine vertebra L2–L4; RCE,
red clover extract; Troch, trochanter; 2-OH, 2-hydroxyestrone; 16a-OH,
16a-hydroxyestrone.
2P values for intergroup comparisons were determined by unpaired
Student’s t tests. P , 0.05 was considered significant.
3 Log-transformed data.
FIGURE 3 Means 6 SEMs of change in BMD of the CON (n = 40,
black) and treatment (RCE; n = 38, gray) groups at L2–L4, FN, and Troch.
Significant differences were determined by unpaired Student’ t test: **P, 0.01.
BMD, bone mineral density; CON, control; FN, femoral neck; L2–L4, lumbar
spine vertebra L2–L4; RCE, red clover extract; Troch, trochanter.
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[36.43 nmol/L (4.7, 68.2 nmol/L)] compared with the CON
group [0.08 nmol/L (21.4, 1.55 nmol/L)]. At 6 mo, the CON
group retained a mean total equol concentration of 3.02 6
0.67 nmol/L, and the RCE group showed a mean total equol
concentration of 39.80 6 15.68 nmol/L (Figure 5). By 6 mo,
55% (n = 21) of the participants in the RCE group were iden-
tified as equol producers.
Urinary estrogen metabolites
The concentration ratio of 2-OH to 16a-OH estrogen me-
tabolites (Figure 6) was significantly increased (P = 0.026) in
the RCE group [0.64 ng/mL (0.36, 1.00 ng/mL)] compared with
the CON group [20.16 ng/mL (20.67, 0.29 ng/mL)]. There
were no significant differences in the intergroup change of 2-OH
or 16a-OH alone between the RCE and CON groups (Table 2).
Dietary intake
Dietary intake does not include nutrients provided by supple-
mentation in this study (Table 3). There were no significant in-
tergroup differences in habitual dietary intakes found for any of
the nutrients between any of the groups at any point during the
study. A significant effect of time on dietary calcium (P, 0.001),
magnesium (P, 0.001), and protein (P, 0.05) intakes was found.
Bonferroni post hoc tests revealed no significant between-group
differences in nutrient intakes throughout the study. Overall,
there was a significant decrease from baseline in dietary intakes
of calcium, magnesium, and protein in both groups. These amounted
to mean decreases of 2159 and 2143 mg for calcium and 243.7
and 237.6 mg for magnesium in the CON and RCE groups,
respectively.
Plasma lipids
There were no significant differences found for inter- or intra-
group plasma concentrations of TC, HDL, LDL, or triglycerides
(Table 4) throughout the study.
BP
There were no significant differences found for systolic
or diastolic BP change between the RCE or CON groups
(Table 4). BP was well regulated in both groups throughout the
study.
TABLE 2
Bone turnover markers and estrogen metabolites1
Biomarkers Baseline 12 mo Change (95% CI) P2
CON CTx,3 ng/mL 0.40 6 0.03 0.43 6 0.19 0.03 (20.02, 0.07)
RCE CTx,3 ng/mL 0.44 6 0.03 0.39 6 0.16 20.04 (20.09, 0.01) ,0.05
CON P1NP, ng/mL 47.59 6 2.49 48.29 6 3.05 0.71 (25.45, 6.87)
RCE P1NP, ng/mL 47.77 6 2.96 49.33 6 3.49 1.47 (23.88, 6.83) 0.85
CON OPG, pg/mL 1249 6 60.4 1670 6 67.784 420.8 (2278, 1094)
RCE OPG, pg/mL 1212 6 47.2 1692 6 65.04 480.1 (2138, 1273) 0.44
CON RANKL, pg/mL 2.07 6 0.19 1.81 6 0.17 20.26 (20.51, 20.02)
RCE RANKL, pg/mL 1.77 6 0.17 1.77 6 0.18 20.002 (20.35, 0.34) 0.22
CON uOC,3 ng/mL 4.60 6 0.58 4.36 6 0.51 20.24 (21.13, 0.65)
RCE uOC,3 ng/mL 3.52 6 0.31 3.63 6 0.38 0.13 (20.46, 0.73) 0.35
CON OC,3 ng/mL 23.61 6 1.28 24.30 6 1.50 0.69 (21.77, 3.15)
RCE OC,3 ng/mL 24.01 6 1.35 23.98 6 1.64 20.03 (22.40, 2.33) 0.67
CON estradiol, nmol/L 0.03 6 0.01 0.04 6 0.01 0.002 (20.007, 0.01)
RCE estradiol, nmol/L 0.03 6 0.01 0.04 6 0.01 0.01 (20.009, 0.03) 0.42
CON 2-OH,3 ng/mL 10.44 6 1.17 10.54 6 1.43 0.10 (21.78, 1.98)
RCE 2-OH,3 ng/mL 12.11 6 2.15 12.64 6 1.33 0.54 (22.25, 3.33) 0.14
CON 16a-OH,3 ng/mL 4.45 6 0.95 4.44 6 0.94 20.02 (20.95, 0.91)
RCE 16a-OH,3 ng/mL 4.91 6 1.00 4.63 6 1.19 20.29 (21.25, 0.67) 0.96
CON 2-OH:16a-OH,3 ng/mL 3.13 6 0.27 2.98 6 0.17 20.16 (20.67, 0.29)
RCE 2-OH:16a-OH,3 ng/mL 2.77 6 0.19 3.41 6 0.23 0.64 (0.36, 1.00) ,0.05
1Absolute data are presented as means 6 SEM; change data are shown as means (95% CIs). CON, control; CTx,
collagen type 1 cross-linked C-telopeptide; OC, osteocalcin; OPG, osteoprotegerin; P1NP, procollagen type I N-terminal
propeptide; RANKL, receptor activator of nuclear factor k-B ligand; RCE, red clover extract; uOC, undercarboxylated
osteocalcin; 2-OH, 2 hydroxyestrone; 16a-OH, 16a-hydroxyestrone.
2P values for intragroup comparisons were determined by paired Student’s t tests. P , 0.05 was considered
significant.
3 Log-transformed data.
4Within-group paired significance of P , 0.01 from baseline to 12 mo.
FIGURE 4 Means 6 SEMs of change in plasma isoflavone concentra-
tions of the CON (n = 40, black) and RCE (n = 38, gray) groups. Significant
differences were determined by unpaired Student’s t test: **P , 0.01. CON,
control; RCE, red clover extract.
BIOAVAILABLE ISOFLAVONES FOR MENOPAUSE SYMPTOMS 915
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/106/3/909/4822361 by guest on 24 Septem
ber 2018
Physical activity
Physical activity data are shown in Table 5. There was
a significant effect of time on self-reported daily activity
(P , 0.01), and Bonferroni post hoc tests revealed no significant
intergroup differences during the study. There was no significant
difference found in daily training between groups at any point
during the study.
Compliance
At the end of the study, the total number of sachets and pill
containers returned after 12 mo indicated that 97.5% (n = 78) of
all participants (N = 80) achieved a compliance of $95% at
study completion. The mean compliance rate was 96.44%6 0.40%.
There were no significant intergroup differences in compliance rates.
Adverse events
Participants in the CON (n = 1) and RCE groups (n = 2)
reported gastrointestinal problems during the study. Out of the
85 included participants 3.5% (n = 3) dropped out of the study
due to gastrointestinal issues, and there was no significant dif-
ferences between groups. There were no other reported adverse
events, and 12-mo daily intake of RCE was well tolerated.
DISCUSSION
In this 12-mo. double-blind RCT of osteopenic postmenopausal
women, RCE exerted a potent physiological effect against estrogen-
deficient bone loss in postmenopausal women with osteopenia.
Moreover, RCE combined with CDM was found to be more
effective than CDM supplementation alone in preserving bone
density in women with estrogen deficiency. Groups achieved high
baseline equivalence, because there were no significant inter-
group differences in any of the baseline characteristics apart from
BMC at the trochanter where the CON group was significantly
higher (Table 1). All postmenopausal participants were estrogen
deficient throughout the study, as indicated by the low plasma
estrogen concentrations ranging from 0.03 to 0.04 nmol/L. DXA
scans found that 12 mo of treatment with RCEwas more effective
at attenuating expected postmenopausal bone resorption at the
FN, L22L4 region, and trochanter than CDM alone (Figure 3).
The BMD loss from baseline to 12 mo was w2-fold lower at the
FN in the RCE group (20.99%) than the CON group (22.2%);
at the L22L4 region, the CON group lost w3-fold more BMD
(23.05%) than the RCE group (21.04%); and at the trochanter,
there was a 4-fold greater loss in BMD in the CON group
(22.79%) than in the RCE group (20.67%). There were no
significant intergroup differences in BMC change at any skeletal
regions apart from the trochanter, where the RCE group had
significantly less BMC loss than the CON group. This finding is
likely influenced by the significantly higher BMC of the CON
group at the trochanter at baseline. Together, these data suggest
that in certain skeletal locations, RCE improved both bone
mineralization and density, whereas in other locations, the bone
formed was of a higher density, with no significant effect on
mineralization. The significant effects on BMC at other sites
may have been possible with a higher number of participants
(44). The beneficial effects of isoflavone treatments against
estrogen-deficient BMD loss, but not BMC loss, have been
documented in previous RCTs (45). Observational data support
that cortical (denser) bone loss has a greater dependency on
estrogen deficiency than does trabecular (more porous) bone
loss; to test this, a 4-y RCT investigated the effects of ET in
postmenopausal women assessed by high-resolution peripheral
quantitative computed tomography and found that cortical bone
was more responsive to ET than trabecular bone (46). This may
also be the case in the present study, where a greater response to
isoflavone treatment was found at the FN (which is richer in
cortical tissue) than in the lumbar spine. We have previously
demonstrated short-term attenuative effects of a fermented RCE
(37 mg isoflavone aglycones/d) and probiotic treatment on BMD
at the L22L4 region in healthy menopausal women (40). The
spine comprises mostly trabecular bone, and we previously
postulated that a longer treatment duration and a higher dose
may be required to achieve attenuation of BMD loss in cortical
skeletal locations (47). The data from the present study support
this assertion, because BMD loss at the FN and trochanter was
blunted in the RCE group compared with the CON group after
12 mo at a higher dosage. Improvements to BMD in post-
menopausal women given 1 y of ET or bisphosphonates have
been shown to range from w0–2.5% and w4–6%, respectively,
at the spine and w0–0.5% and w0.8–3%, respectively, at the
FN (48, 49). Although the effect of size in the present study is
slightly lower than ET or bisphosphonates, the safer profile and
minimal side effects of RCE support its use in wider patient
groups and its suitability for long-term use. The beneficial ef-
fects of RCE on BMD were further corroborated by plasma CTx
FIGURE 5 Means 6 SEMs of plasma equol concentrations of the CON
(n = 40, black) and RCE (n = 38, gray) groups at baseline and at 6 mo with
a 15-nmol/L equol-producer threshold (dotted line). Paired Student’s t tests
of log-transformed data found a significant increase at 6 mo within the RCE
group alone. ***P , 0.001. CON, control; RCE, red clover extract.
FIGURE 6 Means 6 SEMs of the change in urinary 2-OH to 16a-OH
concentration ratios of the CON (n = 40, black) and RCE (n = 38, gray)
groups from baseline to 12 mo. Unpaired Student’s t tests of log-transformed
data found a significant increase in 2-OH to 16a-OH concentration ratio in
the RCE group compared with the CON group. *P, 0.05 CON, control; RCE,
red clover extract; 2-OH, 2-hydroxyestrone; 16a-OH, 16a-hydroxyestrone.
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(the reference standard from bone resorption) concentrations
(Table 2). After 12 mo, CTx concentrations were significantly
decreased in the RCE group (29.40%) compared with the CON
group (6.76%) (50). No other changes in biomarkers were sig-
nificant between groups. Osteoprotegerin concentrations signif-
icantly increased from baseline in both groups. Although there
was a tendency for higher osteoprotegerin concentrations in the
RCE group than in the CON group, the differences did not achieve
significance. Vitamin D was previously shown to modulate os-
teoblastic osteoprotegerin and RANKL secretion through the
nuclear vitamin D receptor, and thus vitamin D supplementation
in this trial may have contributed to increases in osteoprotegerin
concentrations in both groups, thereby partially obscuring the
potential RCE-mediated effects on osteoprotegerin (51). Iso-
flavones exhibit anti-inflammatory, anti-osteoporotic, and anti-
oxidative bioactivity to varying degrees. The primary isoflavone
constituent in the RCE is formononetin, which has demonstrated
promising capability for these bioactivities (30, 35, 52). A recent
in vitro trial found that formononetin dose-dependently inhibited
RANKL-induced proinflammatory cytokines (TNF-a, IL-1b,
and IL-6) and chemokines (macrophage inflammatory factor-1a,
monocyte chemoattractant protein-1, and regulated upon acti-
vation, normal T-cell expressed and secreted) in primary bone
marrow–derived precursors. Formononetin also suppressed
RANKL-induced osteoclastogenesis by downregulating extra-
cellular signal–regulated kinases, c-Jun N-terminal kinases,
TABLE 4
Plasma lipids and blood pressure1
Group Baseline 12 mo2 Change (95% CI) P3
Total cholesterol, mmol/mL CON (n = 40) 5.64 6 0.16 5.50 6 0.14 20.15 (20.39, 0.10)
RCE (n = 38) 5.54 6 0.14 5.44 6 0.17 20.11 (20.33, 0.12) 0.81
HDL, mmol/mL CON (n = 40) 1.82 6 0.08 1.70 6 0.08 20.13 (20.22, 20.03)
RCE (n = 38) 1.81 6 0.07 1.67 6 0.09 20.14 (20.23, 20.05) 0.80
LDL, mmol/mL CON (n = 40) 3.37 6 0.14 3.08 6 0.14 20.30 (20.51, 20.08)
RCE (n = 38) 3.28 6 0.14 3.15 6 0.13 20.13 (20.34, 0.08) 0.28
Triglycerides, mmol/mL CON (n = 40) 1.38 6 0.10 1.31 6 0.09 20.06 (20.22, 0.10)
RCE (n = 38) 1.16 6 0.06 1.26 6 0.07 0.10 (20.02, 0.21) 0.11
Systolic BP, mm Hg CON (n = 40) 125.7 6 1.88 125.6 6 1.94 20.13 (22.08, 1.82)
RCE (n = 38) 121.8 6 1.66 121.4 6 1.79 20.42 (22.56, 1.71) 0.84
Diastolic BP, mm Hg CON (n = 40) 76.47 6 1.29 75.18 6 1.01 21.29 (22.6, 0.02)
RCE (n = 38) 76.16 6 1.10 76.39 6 1.10 0.24 (21.23, 1.71) 0.12
1Absolute data are presented as means 6 SEMs; change data are shown as means (95% CIs). BP, blood pressure;
CON, control; RCE, red clover extract.
2 There were no significant differences in intergroup changes from baseline. Intragroup comparisons were determined
by paired Student’s t tests. P , 0.05 was considered significant.
3P values for intergroup comparisons determined by unpaired Student’s t tests. P , 0.05 was considered significant.
TABLE 3
Three-day dietary intake1
Group Baseline 6 mo 12 mo
Interaction
P2
Time
P2
Treatment
P2
Energy, kJ CON (n = 40) 6893 6 233.4 6954 6 291 6442 6 265.2
RCE (n = 38) 6795 6 223.4 7104 6 237.6 6796 6 254.1 0.44 0.08 0.68
Protein, g CON (n = 40) 73.27 6 2.51 72.94 6 2.84 68.45 6 2.71
RCE (n = 38) 72.67 6 2.45 73.70 6 2.86 69.11 6 2.93 0.92 ,0.05 0.91
Carbohydrate, g CON (n = 40) 199.3 6 6.75 192.7 6 8.11 185.4 6 7.33
RCE (n = 38) 197.8 6 8.42 199.9 6 8.13 192.7 6 10.09 0.69 0.20 0.71
Lipid, g CON (n = 40) 57.17 6 3.15 59.36 6 3.61 53.79 6 3.31
RCE (n = 38) 54.63 6 2.94 57.94 6 3.63 57.04 6 2.54 0.42 0.35 0.94
Vitamin D,3
mg
CON (n = 40) 4.01 6 0.68 4.98 6 0.91 3.31 6 0.56
RCE (n = 38) 3.62 6 0.63 4.14 6 1.01 3.22 6 0.68 0.44 0.14 0.54
Vitamin K,3
mg
CON (n = 40) 96.71 6 19.45 77.33 6 11.39 73.05 6 11.01
RCE (n = 38) 86.18 6 14.76 86.16 6 12.52 89.55 6 19.68 0.51 0.36 0.43
Calcium, mg CON (n = 40) 866.0 6 49.33 880.9 6 50.27 707.0 6 49.34
RCE (n = 38) 836.5 6 52.42 811.7 6 61.03 693.9 6 45.35 0.74 ,0.001 0.55
Magnesium,
mg
CON (n = 40) 286.8 6 11.14 273.3 6 10.62 242.9 6 9.96
RCE (n = 38) 266.1 6 9.99 289.7 6 13.13 228.5 6 11.51 0.048 ,0.001 0.61
1Absolute data of dietary nutrient intake are presented as means 6 SEMs. These data do not include nutrient intake
from supplements. CON, control; RCE, red clover extract.
2Main effects (treatment and time) and interactions were determined by 2-way repeated-measures ANOVA. P , 0.05
was considered significant. Bonferroni multiple comparison tests were used to compare means when the main effects or
interactions were significant.
3 Log-transformed data.
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protein kinase B, and p38 mitogen-activated protein kinase
signaling, as well as inhibiting nuclear factor of activated T cells-1
activation, c-Fos, and nuclear factor kB; thus suggesting non-
genomic and genomic effects (53). A study of female ovariec-
tomized rats supported that formononetin has the potential to
distinctly influence bone turnover, finding treatment to reduce
osteoclastogenesis by decreasing urinary CTx concentration,
upregulating messenger RNA expression of osteoprotegerin
genes, and decreasing RANKL messenger RNA (30). Oxidized
free radical species also play a role in the activation of RANKL,
induction of osteoclastogenesis, and osteoblast apoptosis; a study
of ovariectomized rats by Mu et al. (52) demonstrated that
formononetin increases glutathione peroxidase, superoxide dis-
mutase, and catalase, decreasing lipid peroxidation. The present
study supports the effects of formononetin-rich RCE and pro-
biotic treatment on bone turnover, although not all mechanisms
reported in previous studies manifested because there was no
effect on osteocalcin or RANKL. 16a-OH estrogen metabolites
are considered more genotoxic and estrogenic than 2-OH es-
trogen metabolites, which have minimal estrogenic potential and
may retain cancer-protective properties (25). RCE treatment in
this study was found to increase the urinary 2-OH to 16a-OH
ratio compared with the CON, thereby promoting more favor-
able estrogen metabolism and potentially reducing cancer risk.
These data suggest that isoflavones exhibit capabilities to encour-
age a less carcinogenic estrogen metabolism (23, 24). Three-
day diet diaries found a significant effect of time on calcium
(,0.001), magnesium (,0.001), and protein (,0.05). There
were no differences detected between groups in any dietary
nutrients at any point during the study, supporting that dietary
nutrient intake differences had minimal influence on the outcomes
of the study (Table 3). To put this into context, a change in
dietary calcium amounted to a percentile change in the NOF-
recommended calcium intake of 213.25% for the CON group
and 211.88% for the RCE group. The calculated optimal mag-
nesium intake based on NOF calcium recommendations at a
2.8:1 ratio is 428.57 mg; the change at the end of the study in
magnesium amounted to a decrease of 210.06% for the CON
group and 28.75% for the RCE group. Combining the contri-
bution of supplementary magnesium and calcium with the di-
etary intake of these minerals shows that both the CON group
and the treatment group were well above recommended intakes
throughout the duration of trial. Overall, the CON group had a
mean total daily intake of 1747 mg Ca and 729.9 mg Mg, and
the RCE group had a mean daily intake of 1733 mg Ca and
715.5 mg Mg. The ratio of total calcium to magnesium intake
ranged from 2.38:1 to 2.53:1 throughout the study. Self-reported
exercise and training remained consistent throughout the study,
and no difference was found between the 2 groups, supporting a
negligible effect of changes in exercise on bone turnover in this
study (54, 55). Equol is a daidzein (a derivative of formononetin)
metabolite produced by anaerobic bacteria and has greater estro-
genic potency than its precursor (42). None of the participants
were found to be equol producers at baseline, and no participant
in the CON group became a producer. After 6 mo of treatment,
55% of the participants in the RCE group became equol producers
(n = 21). This suggests that the probiotics in the RCE positively
influenced the intestinal bacterial milieu of participants, promoting
a profile favorable for equol production. In Western countries,
w30% of the population is capable of equol production, and
equol-producer status is shown to be higher in vegetarians,
where w60% are producers (56). Isoflavones typically occur
as glycosides in plants and in most food products. Glycosides
are hydrophilic and have higher molecular weights that pre-
vent passive diffusion across the intestinal brush border; they
require hydrolytic conversion by glycosidases to more apolar,
lipophilic, and lower–molecular-weight aglycones to facilitate
absorption (57, 58). Liquid chromatography-mass spectrome-
try analyses have determined that the fermented RCE given to
participants in the present study provided mostly isoflavone
aglycones (w97.1%) and found the mean isoflavone plasma
concentrations to increase from 714 to 4647 ng/mL after 12 mo in
the RCE group. An RCT of postmenopausal women receiving a
higher dose than the present study of 100 mg aglycone equiva-
lents (glycosides)/d for 30 d showed mean plasma isoflavone
concentrations of 1251 ng/mL; in contrast, in the present study,
we found .3-fold higher plasma concentrations of isoflavone
when given a dose of 57.45 mg/d of isoflavones (59). These
findings support the important role of isoflavone molecular
form and the intestinal microbiome in isoflavone uptake, me-
tabolism, and ultimately therapeutic efficacy.
Limitations
A study duration of $2 y would incorporate $3 complete
bone remodeling cycles; this would further strengthen the evi-
dence provided by DXA in this trial. The use of high-resolution
peripheral quantitative computed tomography in this study would
have facilitated a more comprehensive and greater distinction of
isoflavone effects on cortical compared with trabecular bone (46).
TABLE 5
Physical activity and training1
Group Baseline 6 mo 12 mo
Interaction
P2
Time
P2
Treatment
P2
Daily
activity
CON (n = 40) 2.16 6 0.2 2.56 6 0.2 1.94 6 0.19
RCE (n = 38) 1.86 6 0.17 2.21 6 0.15 1.97 6 0.18 0.20 ,0.01 0.19
Training CON (n = 40) 2.10 6 0.13 1.98 6 0.14 2.19 6 0.14
RCE (n = 38) 1.93 6 0.13 2.21 6 0.15 2.22 6 0.16 0.09 0.12 0.83
1Absolute data of physical activity and training are presented as means 6 SEMs. CON, control; RCE, red clover
extract.
2Main effects (treatment and time) and interactions were determined by 2-way repeated measures ANOVA. P , 0.05
was considered significant. Bonferroni multiple comparison tests were used to compare means when the main effects or
interactions were significant.
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Including other biomarkers of bone turnover would provide a
more comprehensive overview of bone-turnover mechanisms,
particularly sclerostin (an ERb–mediated pre-resorptive marker
produced by osteocytes) and bone-specific alkaline phosphatase
from osteoblasts (37–39, 60). Methods determining food intake,
although comprehensive, are subject to bias and only cover a
small window of the total duration of the study (9 d). Self-report
measures in this study are subjective and open to various biases,
especially recall bias and response bias. The specific participant
type (postmenopausal) and number could represent a limitation
of this study with regards to generalizability. In the case of plasma
lipids or ambulatory BP, all participants in this study were nor-
motensive and were not overweight; hypertensive and obese par-
ticipants would be better suited to investigate potential effects.
Interactions of multiple treatment components with the same
biomarker obscure the beneficial effects of single components.
In conclusion, this study demonstrates that bioavailable RC
isoflavones combined with probiotics potently attenuated estrogen-
deficient BMD loss and improved bone turnover in postmenopausal
osteopenic women. Bioavailable RCE enhanced the efficacy of
traditional CaD (with magnesium) treatment against bone loss.
RCE was also found to increase the equol-producing capabilities
of participants. The bone-sparing properties of isoflavones found
in this study appear to be enhanced when barriers to uptake are
overcome by maintaining isoflavones in aglycone form through
fermentation and by providing probiotics to improve intestinal
uptake and isoflavone metabolism. Moreover, RCE promoted
more favorable estrogen metabolism by increasing the 2-OH to
16a-OH metabolite ratio, thereby indicating the potential to
reduce cancer risk.
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13. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and
risk of ovarian cancer: systematic review and meta-analysis. Hum
Reprod Update 2007;13:453–63.
14. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, Wang B. Hormone
replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol
Oncol 2008;108:641–51.
15. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA,
Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, et al.
Health risks and benefits 3 years after stopping randomized treatment
with estrogen and progestin. JAMA 2008;299:1036–45.
16. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC,
Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, et al.
Health outcomes after stopping conjugated equine estrogens among
postmenopausal women with prior hysterectomy: a randomized con-
trolled trial. JAMA 2011;305:1305–14.
17. Jung W, Yu O, Lau S-MC, O’Keefe DP, Odell J, Fader G,
McGonigle B. Identification and expression of isoflavone synthase, the
key enzyme for biosynthesis of isoflavones in legumes. Nat Biotechnol
2000;18:208–12.
18. Burns KA. Korach KS. Estrogen receptors and human disease: an
update. Arch Toxicol 2012;86:1491–504.
19. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T,
Engström O, Ohman L, Greene GL, Gustafsson JA, Carlquist M.
Molecular basis of agonism and antagonism in the oestrogen receptor.
Nature 1997;389:753–8.
20. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J,
Tujague M, Ström A, Treuter E, Warner M, et al. Estrogen receptors:
how do they signal and what are their targets. Physiol Rev 2007;87:
905–31.
21. Soukup ST, Al-Maharik N, Botting N, Kulling SE. Quantification of
soy isoflavones and their conjugative metabolites in plasma and urine:
an automated and validated UHPLC-MS/MS method for use in large-
scale studies. Anal Bioanal Chem 2014;406:6007–20.
22. Morimoto Y, Maskarinec G, Park S-Y, Ettienne R, Matsuno RK,
Long C, Steffen AD, Henderson BE, Kolonel LN, Le Marchand L,
et al. Dietary isoflavone intake is not statistically significantly associ-
ated with breast cancer risk in the multiethnic cohort. Br J Nutr 2014;
112:976–83.
23. Sampson JN, Falk RT, Schairer C, Moore SC, Fuhrman BJ, Dallal CM,
Bauer DC, Dorgan JF, Shu X, Zheng W, et al. Association of estrogen
metabolism with breast cancer risk in different cohorts of post-
menopausal women. Cancer Res 2016;77:918–25.
BIOAVAILABLE ISOFLAVONES FOR MENOPAUSE SYMPTOMS 919
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/106/3/909/4822361 by guest on 24 Septem
ber 2018
24. Ronis MJJ. Effects of soy containing diet and isoflavones on cyto-
chrome P450 enzyme expression and activity. Drug Metab Rev 2016;
48:331–41.
25. Gupta M, McDougal A, Safe S. Estrogenic and antiestrogenic activities
of 16a- and 2-hydroxy metabolites of 17b-estradiol in MCF-7 and T47D
human breast cancer cells. J Steroid Biochem Mol Biol 1998;67:413–9.
26. Beck V, Rohr U. Jungbauer A. Phytoestrogens derived from red clover:
an alternative to estrogen replacement therapy? J Steroid Biochem Mol
Biol 2005;94:499–518.
27. Okabe Y, Shimazu T, Tanimoto H. Higher bioavailability of isoflavones
after a single ingestion of aglycone-rich fermented soybeans compared
with glucoside-rich non-fermented soybeans in Japanese post-
menopausal women. J Sci Food Agric 2011;91:658–63.
28. Timan P, Rojanasthien N, Manorot M, Sangdee C, Teekachunhatean S.
Effect of synbiotic fermented milk on oral bioavailability of isoflavones
in postmenopausal women. Int J Food Sci Nutr 2014;65:761–7.
29. Lipovac M, Pfitscher A, Hobiger S, Laschitz T, Imhof M, Chedraui P,
Jungbauer A. Red clover isoflavone metabolite bioavailability is de-
creased after fructooligosaccharide supplementation. Fitoterapia 2015;
105:93–101.
30. Tyagi AM, Srivastava K, Singh AK, Kumar A, Changkija B, Pandey R,
Lahiri S, Nagar GK, Yadav DK, Maurya R, et al. Formononetin re-
verses established osteopenia in adult ovariectomized rats. Menopause
2012;19:856–63.
31. Kaczmarczyk-Sedlak I, Wojnar W, Zych M, Ozimina-Kaminska E,
Taranowicz J, Siwek A. Effect of formononetin on mechanical prop-
erties and chemical composition of bones in rats with ovariectomy-
induced osteoporosis. Evid Based Complement Alternat Med 2013;
2013:457052.
32. Pru JK. The bone-promoting actions of formononetin in established
osteopenia. Menopause 2012;19:843–4.
33. Khattab HAH, Ardawi MS, Ateeq RAM. Effect of phytoestrogens
derived from red clover (Trifolium pratense L.) in ovariectomized rats.
Life Sci J 2013;10:1485–97.
34. Ma HR, Wang J, Qi HX, Gao YH, Pang LJ, Yang Y, Wang ZH,
Duan MJ, Chen H, Cao X, et al. Assessment of the estrogenic activities
of chickpea (Cicer arietinum L) sprout isoflavone extract in ovariec-
tomized rats. Acta Pharmacol Sin 2013;34:380–6.
35. Gautam AK, Bhargavan B, Tyagi AM, Srivastava K, Yadav DK, Kumar M,
Singh A, Mishra JS, Singh AB, Sanyal S, et al. Differential effects of
formononetin and cladrin on osteoblast function, peak bone mass
achievement and bioavailability in rats. J Nutr Biochem 2011;22:318–27.
36. Srivastava K, Tyagi AM, Khan K, Dixit M, Lahiri S, Kumar A,
Changkija B, Khan MP, Nagar GK, Yadav DK, et al. Isoformononetin,
a methoxydaidzein present in medicinal plants, reverses bone loss in
osteopenic rats and exerts bone anabolic action by preventing osteoblast
apoptosis. Phytomedicine 2013;20:470–80.
37. Chiang S-S, Pan T-M. Beneficial effects of phytoestrogens and their
metabolites produced by intestinal microflora on bone health. Appl
Microbiol Biotechnol 2013;97:1489–500.
38. Salari Sharif P, Nikfar S, Abdollahi M. Prevention of bone resorption
by intake of phytoestrogens in postmenopausal women: a meta-analysis.
Age (Dordr) 2011;33:421–31.
39. Coxam V. Phyto-oestrogens and bone health. Proc Nutr Soc 2008;67:
184–95.
40. Thorup AC, Lambert MN, Kahr HS, Bjerre M, Jeppesen PB. Intake of
novel red clover supplementation for 12 weeks improves bone status in
healthy menopausal women. Evidence-Based Complement Altern Med
2015;2015:1–11.
41. Klug TL, Bradlow HL, Sepkovic DW. Monoclonal antibody-based
enzyme immunoassay for simultaneous quantitation of 2- and 16
alpha-hydroxyestrone in urine. Steroids 1994;59:648–55.
42. Nettleton JA, Greany JA, Adlercreutz H, Wangen KE, Thomas W,
Kurzer M. Plasma phytoestrogens are not altered by probiotic con-
sumption in postmenopausal women with and without a history of
breast cancer. J Nutr 2004;134:1998–2003.
43. Lydeking-Olsen E, Beck JE, Setchell KDR, Holm-Jensen T. Soymilk
or progesterone for prevention of bone loss: a 2 year randomized,
placebo-controlled trial. Eur J Nutr 2004;43:246–57.
44. Deng H-W, Xu F-H, Davies KM, Heaney R, Recker RR. Differences in
bone mineral density, bone mineral content, and bone areal size in
fracturing and non-fracturing women, and their interrelationships at the
spine and hip. J Bone Miner Metab 2002;20:358–66.
45. Ma D-F, Qin L-Q, Wang P-Y, Katoh R. Soy isoflavone intake increases
bone mineral density in the spine of menopausal women: meta-analysis
of randomized controlled trials. Clin Nutr 2008;27:57–64.
46. Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of
estrogen with micronized progesterone on cortical and trabecular bone
mass and microstructure in recently postmenopausal women. J Clin
Endocrinol Metab 2013;98:E249–57.
47. Parfitt AM. Age-related structural changes in trabecular and cortical
bone: cellular mechanisms and biomechanical consequences. Calcif
Tissue Int 1984;36:S123–8.
48. Middleton ET. Steel SA. The effects of short-term hormone re-
placement therapy on long-term bone mineral density. Climacteric
2007;10:257–63.
49. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD,
Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC,
et al. Ten years’ experience with alendronate for osteoporosis in
postmenopausal women. N Engl J Med 2004;350:1189–99.
50. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P,
Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, et al.
Markers of bone turnover for the prediction of fracture risk and
monitoring of osteoporosis treatment: a need for international reference
standards. Osteoporos Int 2011;22:391–420.
51. Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U,
O’Loughlin PD, Nicholson GC, Briffa KH, Eisman JA, Gardiner EM.
Vitamin D action and regulation of bone remodeling: suppression of
osteoclastogenesis by the mature osteoblast. J Bone Miner Res 2006;
21:1618–26.
52. Mu H, Bai Y-H, Wang S-T, Zhu Z-M, Zhang Y-W. Research on anti-
oxidant effects and estrogenic effect of formononetin from Trifolium
pratense (red clover). Phytomedicine 2009;16:314–9.
53. Huh JE, Lee WI, Kang JW, Nam D, Choi DY, Park DS, Lee SH,
Lee JD. Formononetin attenuates osteoclastogenesis via suppressing
the RANKL-induced activation of NF-kB, c-Fos, and nuclear factor of
activated T-cells cytoplasmic 1 signaling pathway. J Nat Prod 2014;77:
2423–31.
54. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C,
Harbour RT, Caldwell LM, Creed G. Exercise for preventing and
treating osteoporosis in postmenopausal women. Cochrane Database
Syst Rev 2011;CD000333.
55. Rivas A, Romero A, Mariscal-Arcas M, Monteagudo C, Feriche B,
Lorenzo ML, Olea F. Mediterranean diet and bone mineral density in
two age groups of women. Int J Food Sci Nutr 2013;64:155–61.
56. Franke AA, Lai JF, Halm BM, Pagano I, Kono N, Mack WJ, Hodis HN.
Equol production changes over time in postmenopausal women. J Nutr
Biochem 2012;23:573–9.
57. Nielsen ILF, Williamson G. Review of the factors affecting bio-
availability of soy isoflavones in humans. Nutr Cancer 2007;57:1–10.
58. Setchell KDR, Brown NM, Zimmer-Nechemias L, Brashear WT,
Wolfe BE, Kirschner AS, Heubi JE. Evidence for lack of absorption of
soy isoflavone glycosides in humans, supporting the crucial role of
intestinal metabolism for bioavailability. Am J Clin Nutr 2002;76:447–
53.
59. Mathey J, Lamothe V, Coxam V, Potier M, Sauvant P. Bennetau-
Pelissero CB. Concentrations of isoflavones in plasma and urine of
post-menopausal women chronically ingesting high quantities of soy
isoflavones. J Pharm Biomed Anal 2006;41:957–65.
60. Liang HD, Yu F, Lv P, Zhao ZN, Tong ZH. Role of Sost in Wnt signal
pathway in osteoporosis rats and regulating effect of soybean iso-
flavones on Wnt signal pathway. Mol Biol Rep 2014;41:4447–54.
920 LAMBERT ET AL.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/106/3/909/4822361 by guest on 24 Septem
ber 2018
